Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)

Henno, Sébastien; Jeanne, C; Rouge, T. De La Motte; Genestie, Catherine; Treilleux, Isabelle; Croce, Sabrina; Just, Pierre‐Alexandre; Frère-Belda, M A Le; Guinaudeau, E; Penault–Llorca, F; Arnould́, Laurent; Mery-Lamarche, Eliane; Leroux, Agnès; Lemaire, A.; Avérous, Gerlinde; Renaud, O; Charafe-Jauffret, E; Bonneau, C; Leaha, C; Devouassoux‐Shisheboran, Mojgan

doi:10.1016/j.ygyno.2022.03.019

Cited by 5 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 ), by contrast to HNF1β which was heterogeneously expressed in the initial tumor. Taken with the histological analysis, the patient has been diagnosed with OCCC and this diagnosis was confirmed by a histological second opinion of a pathologist expert of the network of rare malignant tumors of the ovary (TMRG) [ 25 ]. Interestingly, PDX (X) displayed a similar heterogeneous HNF1β expression pattern, as well as PDTO (O).…”

Section: Resultsmentioning

confidence: 97%

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Thorel,

Morice,

Paysant

et al. 2023

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background In the era of personalized medicine, the establishment of preclinical models of cancer that faithfully recapitulate original tumors is essential to potentially guide clinical decisions. Methods We established 7 models [4 cell lines, 2 Patient-Derived Tumor Organoids (PDTO) and 1 Patient-Derived Xenograft (PDX)], all derived from the same Ovarian Clear Cell Carcinoma (OCCC). To determine the relevance of each of these models, comprehensive characterization was performed based on morphological, histological, and transcriptomic analyses as well as on the evaluation of their response to the treatments received by the patient. These results were compared to the clinical data. Results Only the PDX and PDTO models derived from the patient tumor were able to recapitulate the patient tumor heterogeneity. The patient was refractory to carboplatin, doxorubicin and gemcitabine, while tumor cell lines were sensitive to these treatments. In contrast, PDX and PDTO models displayed resistance to the 3 drugs. The transcriptomic analysis was consistent with these results since the models recapitulating faithfully the clinical response grouped together away from the other classical 2D cell culture models. We next investigated the potential of drugs that have not been used in the patient clinical management and we identified the HDAC inhibitor belinostat as a potential effective treatment based on PDTO response. Conclusions PDX and PDTO appear to be the most relevant models, but only PDTO seem to present all the necessary prerequisites for predictive purposes and could constitute relevant tools for therapeutic decision support in the context of these particularly aggressive cancers refractory to conventional treatments.

show abstract

Section: Resultsmentioning

confidence: 97%

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Thorel,

Morice,

Paysant

et al. 2023

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Thus, accurate diagnosis is crucial since each subtype has a specific prognostic and surgical treatment [12]. Yet, according to a recent study, these tumors represent the second category, after ovarian mucinous tumors, with the most diagnostic discrepancies between the first diagnosis made by the pathologist and the final review by the expert gynecologic pathologist [13], underlining the inherent diagnostic difficulty of these neoplasms. These diagnostic difficulties stem from the rarity of these lesions, the morphological overlap between the neoplasms of this category, and the numerous morphological differential diagnoses [8].…”

Section: Introductionmentioning

confidence: 99%

Relevance of Molecular Pathology for the Diagnosis of Sex Cord–Stromal Tumors of the Ovary: A Narrative Review

Trecourt,

Donzel,

Alsadoun

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian sex cord–stromal tumors (SCSTs) account for 8% of all primary ovarian neo-plasms. Accurate diagnosis is crucial since each subtype has a specific prognostic and treatment. Apart from fibrosarcomas, stromal tumors are benign while sex cord tumors may recur, sometimes with a significant time to relapse. Although the diagnosis based on morphology is straightforward, in some cases the distinction between stromal tumors and sex cord tumors may be tricky. Indeed, the immunophenotype is usually nonspecific between stromal tumors and sex cord tumors. Therefore, molecular pathology plays an important role in the diagnosis of such entities, with pathognomonic or recurrent alterations, such as FOXL2 variants in adult granulosa cell tumors. In addition, these neoplasms may be associated with genetic syndromes, such as Peutz–Jeghers syndrome for sex cord tumors with annular tubules, and DICER1 syndrome for Sertoli–Leydig cell tumors (SLCTs), for which the pathologist may be in the front line of syndromic suspicion. Molecular pathology of SCST is also relevant for patient prognosis and management. For instance, the DICER1 variant is associated with moderately to poorly differentiated SLCTS and a poorer prognosis. The present review summarizes the histomolecular criteria useful for the diagnosis of SCST, using recent molecular data from the literature.

show abstract

Gynecological carcinosarcomas: Overview and future perspectives

Collet,

González López,

Romeo

et al. 2023

Bulletin du Cancer

View full text Add to dashboard Cite

Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)

Cited by 5 publications

References 27 publications

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Relevance of Molecular Pathology for the Diagnosis of Sex Cord–Stromal Tumors of the Ovary: A Narrative Review

Gynecological carcinosarcomas: Overview and future perspectives

Contact Info

Product

Resources

About